Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma

Abstract

There was little evidence of clinical activity for ABT-510, and further evaluation as a single agent for treating advanced renal cell carcinoma is not warranted. The evidence of a favorable safety profile may justify further evaluation in combination therapy.